Talaporfin

Summary

Talaporfin (CHEMBL2111186) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 3
• Chemistry: 711.8 Da · C38H41N5O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111186
Name	Talaporfin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5486799
Molecular formula	C38H41N5O9
Molecular weight	711.8
InChIKey	SIEXFRDYNDREBM-BRXYURPTSA-N

SMILES: CCC1=C(C2=CC3=C(C(=C(N3)C=C4[C@H]([C@@H](C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=O)O)CC(=O)N[C@@H](CC(=O)O)C(=O)O)CCC(=O)O)C)C)C=C)C

IUPAC name: (2S)-2-[[2-[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-17-ethenyl-12-ethyl-2,8,13,18-tetramethyl-2,3,23,24-tetrahydroporphyrin-5-yl]acetyl]amino]butanedioic acid

Also known as: Talaporfin, Talaporfina, Talaporfine, TALAPORFIN

Parent form; salt/anhydrous children: CHEMBL2107806

Patent coverage: 1,513 distinct patent families (6,108 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,971 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00068068	PHASE2	COMPLETED	Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
NCT00083785	PHASE2	COMPLETED	Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases
NCT00102115	PHASE1	TERMINATED	Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).